Article

Exploration of the influence of GOLGA8B on prostate cancer progression and resistance of castration-resistant prostate cancer to cabazitaxel

2023-11-16

Abstract excerpt

Castration-resistant prostate cancer (CRPC) is the final stage of prostate cancer (PCa). Cabazitaxel is a taxane chemotherapy drug used in treating CRPC. However, patients with CRPC will eventually develop resistance to cabazitaxel, but the mechanism remains unclear. Here, we aimed to investigate potential genetic alterations that may play a role in CRPC resistance to cabazitaxel. Using RNA-sequence data from GSE1...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e8606ac8-f296-5bfe-ad83-3a415f55a911
DOI: 10.21203/rs.3.rs-3452429/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploration of the influence of GOLGA8B on prostate cancer progression and resistance of castration-resistant prostate cancer to cabazitaxelDOI 10.21203/rs.3.rs-3452429/v1Read

Gene Expression Changes and Associated Pathways Involved in the Progression of Prostate Cancer Advanced StagesSemantic proximity Read

Identification and Validation of Four Novel Biomarkers Involved in Docetaxel Resistant Prostate CancerSemantic proximity Read

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancerSemantic proximity Read

Identification of Key Genes and Molecular Mechanisms Associated With Docetaxel Resistance in Castration Resistant Prostate Cancer Based on Bioinformatics AnalysisSemantic proximity Read

SPP1 Promotes Enzalutamide Resistance and EMT Activation in CRPC Progression via PI3K/AKT and ERK1/2 PathwaysSemantic proximity Read

Identification of key molecules for castration resistance prostate cancer by bioinformatic analysisSemantic proximity Read

Integrated Bioinformatics Analysis Identified ASNS and DDIT3 as the Therapeutic Target in Castrate-Resistant Prostate CancerSemantic proximity Read

Gene expression profiling analysis of castration-resistant prostate cancer.Semantic proximity Read

Exploration and Identification of Potential Therapeutic Targets and Biomarkers for Docetaxel Resistant Prostate CancerSemantic proximity Read

Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.Semantic proximity Read

FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer.Semantic proximity Read

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glanceSemantic proximity Read